HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 126 participants.
Also called NCT07123779
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 126 participants
- Sponsor
- 35Pharma Inc., a GSK company
- Registry
-
NCT07123779
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07123779. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-21 (actual); primary completion 2029-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
- Condition
- Pulmonary Hypertension
- Intervention (Biological)
- HS235
- Intervention (Other)
- Placebo
- Lead sponsor
- 35Pharma Inc., a GSK company
Record details
- Record id
cardio:ct-nct07123779- Content hash
b751b97e7acf8af347009d699d19c661c39a25915ee0e6d87005c945fe3a6e39